Approved Symbol |
Approved Name |
Location |
Source |
ITGAL |
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) |
16p13.1-p11 |
Mapped by CNV |
FGF4 |
fibroblast growth factor 4 |
11q13.3 |
Mapped by significant region |
FGF9 |
fibroblast growth factor 9 (glia-activating factor) |
13q11-q12 |
Mapped by significant region |
ACTN3 |
actinin, alpha 3 |
11q13-q14 |
Mapped by significant region |
FN1 |
fibronectin 1 |
2q34 |
Mapped by significant region |
TMSB4Y |
thymosin beta 4, Y-linked |
Y |
Mapped by PBA pathway |
MAPK1 |
mitogen-activated protein kinase 1 |
22q11.2 |
Mapped by LD-proxy |
APC |
adenomatous polyposis coli |
5q21-q22 |
Mapped by LD-proxy; Mapped by PBA pathway |
CYFIP1 |
cytoplasmic FMR1 interacting protein 1 |
15q11 |
Mapped by significant region |
CYFIP2 |
cytoplasmic FMR1 interacting protein 2 |
5q34 |
Mapped by significant region |
MYLPF |
myosin light chain, phosphorylatable, fast skeletal muscle |
16p11.2 |
Mapped by CNV |
RDX |
radixin |
11q23 |
Mapped by significant region |
BDKRB2 |
bradykinin receptor B2 |
14q32.1-q32.2 |
Mapped by PBA pathway |
PPP1CA |
protein phosphatase 1, catalytic subunit, alpha isozyme |
11q13 |
Mapped by significant region |
PAK7 |
p21 protein (Cdc42/Rac)-activated kinase 7 |
20p12 |
Mapped by CNV |
BCAR1 |
breast cancer anti-estrogen resistance 1 |
16q22-q23 |
Mapped by significant region |
CRKL |
v-crk sarcoma virus CT10 oncogene homolog (avian)-like |
22q11.21 |
Mapped by CNV |
CHRM3 |
cholinergic receptor, muscarinic 3 |
1q41-q44 |
Mapped by CNV; Mapped by PBA pathway |
PDGFD |
platelet derived growth factor D |
11q22.3 |
Mapped by significant region |
CHRM5 |
cholinergic receptor, muscarinic 5 |
15q26 |
Mapped by CNV; Mapped by PBA pathway |
ROCK2 |
Rho-associated, coiled-coil containing protein kinase 2 |
2p24 |
Mapped by significant region |
GSN |
gelsolin |
9q33 |
Mapped by PBA pathway; Mapped by significant region |
CHRM1 |
cholinergic receptor, muscarinic 1 |
11q12-q13 |
Mapped by PBA pathway; Mapped by significant region |
PAK1 |
p21 protein (Cdc42/Rac)-activated kinase 1 |
11q13-q14 |
Mapped by significant region |
MAPK3 |
mitogen-activated protein kinase 3 |
16p11.2 |
Mapped by CNV |
WASL |
Wiskott-Aldrich syndrome-like |
7q31.3 |
Mapped by CNV |
ARPC5L |
actin related protein 2/3 complex, subunit 5-like |
9q34.11 |
Mapped by significant region |
CFL1 |
cofilin 1 (non-muscle) |
11q13.1 |
Mapped by significant region |
ARPC5 |
actin related protein 2/3 complex, subunit 5, 16kDa |
1q |
Mapped by significant region |
PIK3R1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
5q13.1 |
Mapped by significant region |
ARPC2 |
actin related protein 2/3 complex, subunit 2, 34kDa |
2q36.1 |
Mapped by significant region |
PIK3CG |
phosphoinositide-3-kinase, catalytic, gamma polypeptide |
7q22 |
Mapped by CNV |
ARHGEF4 |
Rho guanine nucleotide exchange factor (GEF) 4 |
2q22 |
Mapped by CNV; Mapped by significant region |
SSH3 |
slingshot homolog 3 (Drosophila) |
11q13 |
Mapped by significant region |
FGF3 |
fibroblast growth factor 3 |
11q13 |
Mapped by significant region |
FGF19 |
fibroblast growth factor 19 |
11q13.1 |
Mapped by significant region |
ARHGEF12 |
Rho guanine nucleotide exchange factor (GEF) 12 |
11q23.3 |
Mapped by significant region |
FGD3 |
FYVE, RhoGEF and PH domain containing 3 |
9q22 |
Mapped by significant region |
IQGAP2 |
IQ motif containing GTPase activating protein 2 |
5q |
Mapped by CNV |
ITGA2 |
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) |
5q11.2 |
Mapped by LD-proxy |
INS |
insulin |
11p15.5 |
Mapped by literature SNP |